Table 2.

Estimates of Benefit to Harm and Cancer Probability Across Risk Strata in Full Validation Cohort

Variable	Risk Strata
	LR (1%-9%)		MR (10%-34%)		IR (35%-69%)		HR (70%-84%)		VHR (85%-100%)
	Benign	Malignant	Benign	Malignant	Benign	Malignant	Benign	Malignant	Benign	Malignant
Mayo Clinic model, n	78	4	156	50	37	94	5	47	1	17
RRM, n	101	6	139	57	19	34	16	58	2	57
Benefit to harm analysesa	TN to FN Ratio				. . .		TP to FP Ratio
Mayo Clinic model	19.5		3.1				9.4		17.0
RRM	16.8		2.4				3.6		28.5
Cancer probabilityb
Mayo Clinic model	4.9 (4 of 82)		24.3 (50 of 206)		71.8 (94 of 131)		90.4 (47 of 52)		94.4 (17 of 18)
RRM	5.9 (6 of 101)		29.1 (57 of 196)		64.2 (34 of 53)		78.4 (58 of 74)		96.6 (57 of 59)
Likelihood ratio (stratum specific)
Mayo Clinic model	0.07		0.42		3.32		12.28		22.21
RRM	0.08		0.54		2.34		4.74		37.24
Estimated cancer probability, %b
Mayo Clinic model	2.2		12.2		52.5		80.4		88.1
RRM	2.5		15.2		43.8		61.2		92.5

Data are presented as percentage (No./total No.), unless otherwise indicated. FN = false-negative; FP = false-positive; HR = high-risk; IR = intermediate risk; LR = low risk; MR = moderate risk; RRM = risk reclassification model; TN = true-negative; TP = true-positive; VHR = very high risk.

^aBenefit to harm analysis performed by calculation of within strata of TN to FN ratio for LR and MR categories and TP to FP ratio for HR and VHR categories.

^bCancer probability within strata estimated at 25% prevalence.